Advisory Research Inc Mirati Therapeutics, Inc. Transaction History

Advisory Research Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 12, 2020	SELL	$69.78 - $116.21 $716,919 - $1.19 Million	-10,274 Closed	0 $0
Q4 2019 Feb 11, 2020	BUY	$70.76 - $128.86 $292,097 - $531,934	4,128 Added 67.17%	10,274 $1.32 Million
Q3 2019 Nov 12, 2019	SELL	$77.91 - $109.6 $601,776 - $846,550	-7,724 Reduced 55.69%	6,146 $479,000
Q2 2019 Aug 14, 2019	BUY	$59.49 - $104.71 $825,126 - $1.45 Million	13,870 New	13,870 $1.43 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

Stay updated on Advisory Research Inc with notifications on news.